US › Healthcare

Eterna Therapeutics Inc (ERNA)

US · Healthcare · Biotechnology

$4.42+28.12%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-5.5M

Profit YoY

+32.9%

EPS

$-6.95

EPS estimate

$-1.95

EPS came in at -6.95 against a street estimate of -1.95 — a miss of 256.4%.

Key statistics

Market cap

$3.8M

Forward P/E

0.0

P/B

0.56

Book value

$5.88

EPS (TTM)

$-5.19

52-week high

$48.00

52-week low

$3.18

50-day MA

$6.82

200-day MA

$17.11

Beta

2.51

Analyst view

with an average price target of $30.00.

Shareholding

Insiders

41.74%

Institutions

10.15%

Largest institutional holders

Fund	Stake
CI Private Wealth LLC	1.50%
Geode Capital Management, LLC	0.84%
Warberg Asset Management LLC	0.17%
Vanguard Group Inc	0.12%
Citadel Advisors Llc	0.11%
Vanguard Capital Management, LLC	0.09%
Vanguard Fiduciary Trust Co	0.09%
UBS Group AG	0.07%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Eterna Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.